Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $81.2 million.

  • Ligand Pharmaceuticals' Total Non-Current Liabilities rose 504.54% to $506.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $506.7 million, marking a year-over-year increase of 504.54%. This contributed to the annual value of $81.2 million for FY2024, which is 38.65% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Total Non-Current Liabilities of $81.2 million as of FY2024, which was up 38.65% from $58.5 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Total Non-Current Liabilities registered a high of $621.9 million during FY2020, and its lowest value of $58.5 million during FY2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Total Non-Current Liabilities value was $81.2 million (recorded in 2024), while the average stood at $92.4 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Total Non-Current Liabilities crashed by 69.78% in 2022 and then spiked by 38.65% in 2024.
  • Ligand Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $621.9 million in 2020, then decreased by 26.89% to $454.7 million in 2021, then tumbled by 69.78% to $137.4 million in 2022, then crashed by 57.40% to $58.5 million in 2023, then skyrocketed by 38.65% to $81.2 million in 2024.